Literature DB >> 12763420

Waking up to sleeping sickness.

August Stich1, Michael P Barrett, Sanjeev Krishna.   

Abstract

Devastating epidemics of human African trypanosomiasis are currently re-emerging in many sub-Saharan countries. In the past three decades, clinical research into this important disease has been neglected, as have urgently needed initiatives on drug development, disease surveillance and vector control. Recent impetus has aimed to provide a free supply of antitrypanosomal drugs, to develop a new orally active trypanocidal agent and to attack the tsetse vector with modern technology. In addition, pan-African initiatives to co-ordinate control efforts have begun. These all provide some hope for the future, but they might not be enough to reverse the resurgence of this deadly disease in the heart of Africa.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763420     DOI: 10.1016/s1471-4922(03)00055-2

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  15 in total

1.  Synthetic nonamer peptides derived from insect defensin mediate the killing of African trypanosomes in axenic culture.

Authors:  Hiroshi Kitani; Jan Naessens; Masanori Kubo; Yoshio Nakamura; Fuad Iraqi; John Gibson; Minoru Yamakawa
Journal:  Parasitol Res       Date:  2009-03-24       Impact factor: 2.289

Review 2.  Chemotherapy for second-stage human African trypanosomiasis.

Authors:  Vittoria Lutje; Jorge Seixas; Adrian Kennedy
Journal:  Cochrane Database Syst Rev       Date:  2013-06-28

Review 3.  Options for field diagnosis of human african trypanosomiasis.

Authors:  François Chappuis; Louis Loutan; Pere Simarro; Veerle Lejon; Philippe Büscher
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 4.  Evolution of a strategy for preparing bioactive small molecules by sequential multicomponent assembly processes, cyclizations, and diversification.

Authors:  James J Sahn; Brett A Granger; Stephen F Martin
Journal:  Org Biomol Chem       Date:  2014-08-19       Impact factor: 3.876

5.  First small molecular inhibitors of T. brucei dolicholphosphate mannose synthase (DPMS), a validated drug target in African sleeping sickness.

Authors:  Terry K Smith; Benjamin L Young; Helen Denton; David L Hughes; Gerd K Wagner
Journal:  Bioorg Med Chem Lett       Date:  2009-01-30       Impact factor: 2.823

6.  The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in african trypanosomes.

Authors:  Harry P de Koning; Laura F Anderson; Mhairi Stewart; Richard J S Burchmore; Lynsey J M Wallace; Michael P Barrett
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.

Authors:  Tanja Wenzler; David W Boykin; Mohamed A Ismail; James Edwin Hall; Richard R Tidwell; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

Review 8.  Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections.

Authors:  G Edwards; S Krishna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-17       Impact factor: 3.267

9.  The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward.

Authors:  Pere P Simarro; Abdoulaye Diarra; Jose A Ruiz Postigo; José R Franco; Jean G Jannin
Journal:  PLoS Negl Trop Dis       Date:  2011-02-22

10.  Estimates of the duration of the early and late stage of gambiense sleeping sickness.

Authors:  Francesco Checchi; João A N Filipe; Daniel T Haydon; Daniel Chandramohan; François Chappuis
Journal:  BMC Infect Dis       Date:  2008-02-08       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.